Novo Nordisk A/S has revised its 2025 sales forecast for the fourth time in 2023, attributing the adjustment to weaker-than-anticipated demand for its leading medications, Wegovy...
Recent research from the University of Utah has unveiled a promising method for enhancing glucagon-like peptide-1 (GLP-1) agonists, potentially paving the way for a new generation...
